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Abstract
Gliomablastoma multiform (GBM) is the most fatal form of all brain cancers in humans. Currently there are limited diagnostic
tools for GBM detection. Here, we applied surprisal analysis, a theory grounded in thermodynamics, to unveil how
biomolecule energetics, specifically a redistribution of free energy amongst microRNAs (miRNAs), results in a system
deviating from a non-cancer state to the GBM cancer –specific phenotypic state. Utilizing global miRNA microarray
expression data of normal and GBM patients tumors, surprisal analysis characterizes a miRNA system response capable of
distinguishing GBM samples from normal tissue biopsy samples. We indicate that the miRNAs contributing to this system
behavior is a disease phenotypic state specific to GBM and is therefore a unique GBM-specific thermodynamic signature.
MiRNAs implicated in the regulation of stochastic signaling processes crucial in the hallmarks of human cancer, dominate
this GBM-cancer phenotypic state. With this theory, we were able to distinguish with high fidelity GBM patients solely by
monitoring the dynamics of miRNAs present in patients’ biopsy samples. We anticipate that the GBM-specific
thermodynamic signature will provide a critical translational tool in better characterizing cancer types and in the
development of future therapeutics for GBM.
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Introduction
Glioblastoma multiforme (GBM) is an aggressive primary brain
tumor that exhibits extremely poor response to current therapies.
Despite maximal therapy with surgical resection, radiation and
temozolomide, survival statistics remain dismal [1,2]. According to
the National Brain Tumor Society, GBM accounts for approxi-
mately 23 percent of all primary brain tumors diagnosed in the
U.S. The prognosis for survival beyond the five-year mark is poor,
and the average survivability for people diagnosed with GBM is
one year [3]. Early diagnosis and treatment however often extend
the quality and length of life for individuals suffering with GBM.
Early detection of high-grade malignancy also significantly
increases the treatment options available and patient survival rate
[4]. Several studies have attempted to identify potential biomark-
ers for GBM. In a study of 125 GBM patients, MGMT promoter
methylation was strongly correlated to GBM survival [5]. In
addition to EGFR amplification, maintenance of PTEN, wild-type
p53 and p16 has also been associated with improved survival in
GBM following chemotherapy [6]. Loss of heterozygosity (LOH)
on chromosome 10q23 in primary GBMs and TP53 mutations in
secondary GBMs has also been well documented in patient studies
[7]. Studies using microRNA (miRNA) arrays and glioma tissues
found that miR-27a was up-regulated in the glioma cell lines and
patients samples by quantitative real-time polymerase chain
reaction (qRT-PCR) and suggest that miR-27a may be implicated
in the progression of glioma through the modulation of
neurotrophin signaling pathway, the MAPK signaling pathway,
the transforming growth factor-b (TGF-b) signaling pathway,
cytokine-cytokine receptor interactions, the p53 signaling path-
way, the apoptotic signaling pathway, as well as others [8]. The
stable expression of a targeting construct against miR-27, an anti-
miR-27 construct, significantly reduced the proliferation and the
accumulation of U87 GBM cells and impaired the invasiveness of
U87 GBM cells in vitro [9]. However, the prognostic value of
these biomarkers has yet to be ascertained and further progress
needs to be made not only to elucidate the mechanisms underlying
the role of these biomarkers in GBM cancer progression but also
to identify others.
MiRNAs are single-stranded short coding RNA molecules of
approximately 22 nucleotides in length. MiRNAs guide the RNA-
induced silencing complex (RISC) to post-transcriptionally repress
the expression of protein-coding genes by binding to targeted
messenger RNAs (mRNAs). MiRNAs constitute only 1–3% of the
human genome, yet are estimated to control approximately one
third of all gene expression. A single miRNA has been observed to
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control over 100 target mRNAs [10]. Conversely, a single mRNA
can be modulated by multiple miRNAs. Over 1,000 miRNAs have
been identified in humans according to a registry (miRBase)
cataloguing all reported discoveries. MiRNAs play crucial
regulatory roles in several cellular processes, including growth,
proliferation, metabolism, development, and apoptosis [11,12].
Given miRNAs widespread regulatory function within the cell, the
aberrant expression of miRNAs has naturally been implicated in
several human diseases, such as diabetes, arthritis, kidney disease,
neurodegenerative disorders and cancer [13]. Studies of genome-
wide miRNA expression have indicated that a majority of human
miRNA genes are located at fragile genomic sites associated with
cancer, and that miRNAs can function both as an oncogene and as
a tumor suppressor. However, understanding how miRNA
dynamics differ between phenotypic states on a systems level has
remained an enigma, particularly in understanding how global
modulations of miRNAs can program a non-cancer state to exhibit
cancer-phenotypic characteristics. Currently there exist several
computational miRNA target prediction tools, which are heavily
dependent on complementarily to miRNA seeds and evolutionary
conservation. Although these features allow for successful target
identification, not all miRNA target sites are conserved and adhere
to canonical seed complementarity.
We applied an unbiased thermodynamic maximal-entropy
based approach, known as surprisal analysis, to examine global
miRNA expression dynamics of 534 miRNAs in over 490 GBM
patients. This theoretical analysis unveils a GBM-specific miRNA
thermodynamic signature capable of distinguishing healthy and
GBM patients with high fidelity. Surprisal analysis also identified a
miRNA system response unique to GBM patients, where miRNAs
implicated in the regulation of stochastic signaling processes
crucial in the hallmarks of human cancer, including cell
proliferation and cancer metabolism, contributed the greatest
free-energy to sustaining the GBM-cancer phenotypic state. We
anticipate that the GBM-specific miRNA signature introduced
here will have substantial translational potential and utility as a
high-throughput drug discovery platform, particularly in better
understanding how current therapeutics can affect biomolecule
dynamics in human cancers.
Results
Surprisal analysis identifies a thermodynamic miRNA
signature unique to GBM.
Significant effort has been made in identifying disease signa-
tures, individual genes or compilations of modulated genes that
can be used to characterize the phenotypic states of disease [14–
16]. Surprisal analysis was applied to the miRNA microarray
expression profiles collected from 490 GBM patients’ tumor tissue
samples and compared to the expression profiles from 10 non-
GBM healthy controls. Surprisal analysis begins with the
identification of a reference defined as the balance state, in which
all cellular processes are assumed at equilibrium and therefore for
which there is no net change in the system, as previously described
by [17]. It is an idealized reference state common to both healthy
and diseased patients. Then, constraints that deviate the system
away from this balance state are determined and characterized.
These constraints unveil observable phenotypic cell states unique
to the system. We not only identify these constraints but also
characterize the signatures, specifically biomolecule dynamics that
are responsible for the deviation of the system from the balance
state into phenotypic states. In the present analysis the by far
dominant signature is the GBM-specific cancer state. The
theoretical analysis quantifies the importance of each miRNA in
each of the system’s signatures.
The list of miRNAs with largest negative values of Gi is shown
in Figure 1. These are the most stable ( = lowest free energy)
miRNAs that sustain the balance state. We find that the largest
contribution of free energy of individual miRNAs to the balance
state is from miRNAs networks involved in maintaining cellular
homeostasis and evolutionary conserved miRNAs. Furthermore,
both GBM systems and normal systems show a very similar
distribution of standard free energy amongst miRNAs in the
balance state, suggesting that GBM cancer and normal systems
may share a common thermodynamic lineage (Figures 1A and
1C). Heat maps of the balance state demonstrate, as expected, that
the expression flux of miRNAs that comprise the balance state is
consistent across all patients. Therefore the balance state is robust
against patient variability (Figure 1B and Figure 1 D). We
anticipate that slight variability (#10%) between GBM patients
may arise from varying amounts of necrotic or dead cells in the
heterogeneous tumor samples prior to microarray processing. We
previously investigated the role of experimental noise by examin-
ing the balance state at different points in time during
carcinogenesis of a homogenous cell population in vitro [18].
In the balance state, we observe the let-7 family of miRNAs; let-
7 and its family members are highly conserved across species in
sequence and function, and misregulation of let-7 leads to a less
differentiated cellular state [19]. Additionally, we see miR-22 in
the balance state, also highly conserved across many vertebrate
species. MiR-22 directly targets histone deacetylases involved in
DNA replication and transcription [20]. Interestingly, we also see
miR-9*, a miR highly expressed in the normal brain and critically
involved in the neuronal differentiation and basic neuronal
function [21] present in the balance state, suggesting that the
balance state not only consists of miRNAs that regulate the basic
cellular functions but also are tissue specific (Table S1).
Many of miRNA functions remain unknown and the mecha-
nisms driving cooperative regulation between miRNAs and their
cellular targets are also still not fully understood. MiRNAs tend to
target highly connected genes in cellular networks. Additionally,
the miRNAs that constitute the balance state are directly related to
the regulation and expression of components of the cellular
homeostasis system, such as chaperones and the cellular machin-
ery involved in the proteasome, cell cycle, autophagy and cell
transport. The health of a cell is inextricably correlated to cellular
quality control, where a highly complex network of molecular
interactions balances protein synthesis, protein function, cellular
metabolism and protein clearance. Deviations from cellular
homeostasis or aberrations in the machinery that regulates
processes associated with cellular homeostasis results in global,
system-wide decline in cellular function, with deleterious conse-
quences on tissue and ultimately patient viability [22]. Therefore,
we sought out to determine the miRNAs that contributed to a
system deviating from the balance state to a cancer specific
phenotypic state.
After determining the miRNAs that contribute to sustaining the
balance state, we next identify the constraints placed on the system
when deviating away from the balance state. Surprisal analysis
identifies the largest deviation away from the balance state and in
our analysis, the largest deviation from the balance state is
revealed to be a unique signature of the disease state. This
constraint is capable of distinguishing healthy and GBM patient
samples and is characterized as specific to the GBM cancer
phenotypic state. We also determine the miRNAs with the greatest
contribution to this GBM cancer phenotypic state and utilize this
miRNA signature to robustly distinguish between healthy and
Surprisal Analysis Delineates a GBM-Specific miRNA Phenotype
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GBM cancer patients (Figure 2A). In addition, the analysis
characterizes degrees of patient variability, or the thermodynamic
potentials of the disease for each patient (Figure 2B and
Figure 2C). These patient-specific potentials in the cancer
phenotypic state may provide an avenue for development of
personalized diagnostics.
In the GBM-specific signature, we identified miRNAs that
regulate critical signaling machinery involved in cell proliferation,
cancer invasiveness and directly affect GBM cancer aggressiveness
(Table S2 and Table S3). For instance, we observe miR-21 to have
the greatest positive free –energy contribution to deviating a
system from a non-GBM state to the GBM cancer state (Table S3
and Fig 2A). Previous studies have revealed elevated miR-21 levels
in human glioblastoma tumor tissues, early-passage glioblastoma
cultures, and in six established glioblastoma cell lines (A172, U87,
U373, LN229, LN428, and LN308) compared with nonneoplastic
fetal and adult brain tissues and compared with cultured
nonneoplastic glial cells. Additionally, knockdown of miR-21 in
cultured glioblastoma cells triggers activation of caspases and leads
to increased apoptotic cell death [23]. Conversely, in the GBM-
specific signature, we identified miR-124 with the largest negative
free-energy contribution to deviating a system from the GBM
cancer state to the non-cancer state (Table S2 and Fig 2A). Studies
have implicated miR-124 as a brain-enriched miRNA that plays a
crucial role in neural development and is down regulated in
glioma and medulloblastoma, suggesting its possible involvement
in brain tumor progression. Additionally, miR-124 is down
regulated in a panel of different grades of glioma tissues and in
human glioma cell lines [24].
Several studies have suggested that miRNA expression behavior
can provide a more accurate method of classifying cancer subtypes
than transcriptome profiling of an entire set of known protein-
coding genes. Differential miRNA expression behavior has been
able to successfully classify poorly differentiated cancers, while
mRNA gene expression behavior failed to classify them [25–28].
Further characterization and understanding of these miRNA
expression behaviors and extension of surprisal analysis to miRNA
datasets will lead to the development of tissue- and biofluid-specific
diagnostic markers, as well as a new type of oligonucleotide-based
therapeutics. We further experimentally validated the GBM-
specific signature by application of surprisal analysis to miRNA
microarray expression profiles (Agilent) from a cohort of 24 GMB
Figure 1. The balance state is common to GBM diseased and healthy patients. The heat map A is a representation that highlights the
invariance across patients where each column is an individual patient. Each row is a different miRNA. The miRNAs with the greatest contribution to
the balance state are listed in order of descending contribution (and decreasing energetic stability, on a ln scale, see inset on the right) where dark is
more stable and yellow is less stable. In the balance state, all patients are exhibiting similar expression pattern. B. The plot shows the patient potential
in the balance state ( = Lagrange multiplier for the balanced state), as described in the methods, vs. the patient index, n, coinciding with the heat
map in A. No significant variation of is observed between healthy and GBM diseased patients, as expected for a balance state that is common to both
GBM and normal patients. C. An alternative graphical representation of the stability of the balanced state. Shown is a histogram of the patient
potentials in the balanced state, computed for the 10 healthy patients and 20 groups of 10 diseased patients each, showing altogether 200 diseased
patients. The histograms is a rather narrow peak, indicating a common value to both healthy and diseased patients. The range of the ordinate in B is
the same as the range of the abscissa used in the histogram. D. Signatures of the balance state of 19 different patient groups, 2 to 20, are shown in
the legend as a scatter plot vs. the signature of patients group 1. Each group has 10 healthy patients and different sets of 10 diseased ones. Despite
patient variability the signatures of the different groups are very consistent across the entire range of (only negative) possible values of Gi.
doi:10.1371/journal.pone.0108171.g001
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patients. These GBM patients were examined and confirmed by
the UCLA Neuro-Oncology and Pathology Departments for high-
grade GBM (Table S4). Additional signatures may be identified by
surprisal analysis (see methods) of expression level data. The second
signature is about half as large as the disease signature. Even so,
sorting between healthy and diseased patients is clear and robust
as shown in Figure 2.
Discussion
Cancer cells frequently exist in varying phenotypic states and
phenotypic equilibrium was observed in cell state-proportions in
vivo and in vitro. Additionally, current anti-cancer therapies
preferentially target specific cancer cell states and initiate changes
in phenotypic properties of tumors [29]. Therefore further
understanding of how cell states are determined, specifically how
a normal cell adopts a new phenotypic state and how this state can
differ for different patients is of considerable interest and will
facilitate the development of targeted and more effective
therapeutics. Surprisal analysis is an information-theoretic ap-
proach grounded in thermodynamics and is capable of character-
izing biomolecule dynamics, such as miRNAs, based on the
expression flux of the biomolecule. We anticipate that under-
standing these biomolecule dynamics will enable us to better
monitor bioenergetics of the system. Surprisal analysis has already
been applied to a spectrum of disciplines including engineering,
physics, chemistry and biomedical engineering and is here used to
thermodynamically characterize biological systems based on
biomolecule cellular dynamics.
We apply surprisal analysis to elucidate a GBM-cancer specific
miRNA signature. This signature was able to distinguish between
healthy and GBM patients. The miRNAs in this signature have
been implicated in cancer progression. Aberrant expression of
microRNA (miRNA) is commonly associated with cancer and loss
of miR-124 has previously been implicated to function as a tumour
suppressor. The expression levels of mature miR-124 in a
retrospective series of 119 cases of histologically confirmed GBM
and found its expression was markedly lower in over 80% of the
Figure 2. The GBM cancer-specific miRNA thermodynamic signature distinguishes GBM and healthy patients. A. The heat map shows
the miRNAs with the greatest contribution to the GBM cancer phenotypic state, up regulated and down regulated with respect to the balanced state
(on a ln scale, see colour code in the inset). Similar thermodynamic behavior is observed across patients, however patient specific variability is
observed. B. The plots shows the patient potential in the disease signature ( = first Lagrange multiplier), on the same scale of patient index, n,
coinciding with the heat map in A. Distinct difference in sign of the lagrange multiplier is observed between healthy and GBM diseased patients,
delineating the two phenotypic states. C. A histogram of the patient potentials in the disease signature computed for the 10 healthy patients and 20
groups of 10 diseased patients each, showing altogether 200 diseased patients. D Different groups of diseased patients have consistent signatures in
both balance state and disease. Disease signatures of 19 different patient groups, 2 to 20, are shown as a scatter plot vs. the signature of patients
group 1. Each group has 10 healthy patients and a different set of 10 diseased ones. The groups are identified in the legend. Despite patient
variability the signatures of the different groups are very consistent across the entire range of possible values of Gi.
doi:10.1371/journal.pone.0108171.g002
Surprisal Analysis Delineates a GBM-Specific miRNA Phenotype
PLOS ONE | www.plosone.org 4 September 2014 | Volume 9 | Issue 9 | e108171
GBM clinical specimens compared to normal brain tissue [30].
MiR-21 is up-regulated in different human cancers including
glioblastoma, prostate and breast cancer. In addition, mir-21
contains oncogenic properties for it has the ability to negatively
modulate the expression of tumor-suppressor genes [31]. Sup-
pression of miR-21 in vitro suppressed both cell growth in vitro
and tumor growth in the xenograft mouse models [32]. MiR-21
was one of the most frequently up regulated miRNA in both
neuronal and GBM cell lines [33]. Antisense-miR-21-treated cells
showed a decreased expression of EGFR, activated Akt, cyclin D,
and Bcl-2 [34]. Consistent with our analysis, previous studies have
also revealed the down-regulation of miR-451 in A172, LN229
and U251 human GBM cells. Increased expression of miR-451 by
administration of miR-451 mimics oligonucleotides reversed the
biology of each of the three cell lines, inhibiting cell growth,
inducing G0/G1 phase arrest and increasing cell apoptosis.
Further, treatment with miR-451 mimics oligonucleotides dimin-
ished the invasive capacity of these cells, as the number of cells
invading through matrigel was significantly decreased [35]. MiR-7
is also found to be a tumor suppressor in GBM, targeting critical
cancer pathways. MiR-7 potently suppressed epidermal growth
factor receptor (EGFR) expression, and furthermore it indepen-
dently inhibited the Akt pathway via targeting upstream regulators
[36]. Patients’ overall survival (OS) and progression-free survival
(PFS) associated with interested miRNAs and miRNA-interactions
as performed by Kaplan-Meier survival analysis of over 400 GBM
patients indicated that that low levels of miR-155 and miR-210
were significantly associated with long OS of GBM patients, and
also showed that high miR-326/miR-130a and low miR-155/
miR-210 were related with extended PFS [37]. Consistent with
many miRNAs present in our GBM-specific signature, we find
that targeting these miRNAs in vitro and in vivo may provide an
effective therapeutic avenue for GBM. Additionally, we unveil
miRNAs critical to the GBM-specific signature that have not yet
been examined experimentally, but may expose new miRNA
targets in GBM.
We anticipate that application of surprisal analysis and further
understanding of patient potentials can also generate predictive
formulations to identify biomarkers of cancer that predict
individual patients benefit or success rates from a particular
targeted therapy. Recent advances in genome technologies and the
outpouring of genomic information related to cancer have
accelerated the convergence of discovery science and clinical
medicine. Our study emphasizes the importance of establishing
the biological relevance of a cancer profiling technologies and
modeling platforms and exploring the clinical potential and
application of their discoveries.
Methods
GBM Tissue Preparation
Fresh human glioblastoma specimens (WHO Grade IV) was
collected from patients following informed written consent at the
David Geffen School of Medicine, University of California, Los
Angles. Samples were submitted to the study under a protocol
approved by the University of California Office of Human
Research Protection and the North General Institutional Review
Board (exempt IRB Protocol # 12-001039). Samples were
obtained from patients who underwent primary therapeutic
subtotal or total tumor resection performed under image guidance.
Tissue samples were obtained at primary resection, and none of
the patients had undergone prior chemotherapy or radiation
therapy. The samples were immediately frozen on dry ice and cut
into 12-mm sections. Histological diagnosis of tumor core and
invasive edge was made by neuropathological review by standard
light-microscopic evaluation of the sections stained with hematox-
ylin and eosin. The targeted areas were collected by microscopic
dissection under an inverted microscope and processed immedi-
ately for RNA isolation. Patient miRNA expression analysis will be
deposited in GeoAsscession and NCBI.
RNA extraction, miRNA microarray profiling
Total RNA, including small RNA, was isolated using the
mirVana miRNA isolation kit (Ambion, Austin, TX). The RNA
quality and quantity were assessed using the NanoDrop 2000
(Thermo Scientific, Waltham, MA). The integrity of RNA was
determined using a Bioanalyzer 2100 Nano LabChip kit (Agilent
Technologies, Santa Clara, CA). Samples selected for the study
contained intact RNA with a RIN$8.0. One hundred ng total
RNA was end-labeled with Cy3-pCp following the manufacturer’s
recommendations using Agilent’s miRNA Complete Labeling and
Hyb Kit (Agilent). Labeled miRNA was hybridized to Agilent’s
Human 8615K miRNA Microarrays (V2) based on Sanger
miRbase (release 10.1). Images were captured using an Agilent
DNA Microarray Scanner set at default settings for miRNA
microarrays. Scanned TIFF images were processed using Feature
Extractor v. 10.5.1.1. Further quality control and normalization
was performed using GeneSpring GX 11 (Agilent). Signals ,1
were set to 1 due to GeneSpring’s analysis in log space, negative
values were converted as well. Values were divided by the 75th
percentile signal on that array to allow for improved comparison
between arrays.
TCGA miRNA dataset and patient information
Level 3 miRNA expression data were obtained from The
Cancer Genome Atlas (TCGA) data portal. MiRNA microarray
expression datasets from glioblastoma multiform were acquired in
August 2012.
Surprisal Analysis
Surprisal analysis was utilized to directly compute the proba-
bility that a particular patient is diseased as previously described
[14,15]. See also the graphical overview provided in the Schematic
S1.
Supporting Information
Schematic S1 Surprisal Analysis of GBM Patient Biopsy
Samples. The balanced state is common to all patients, see
figure 1 of the main text. The balance state is located at the
minimum of the free energy, which is the point of maximal
entropy. The disease phenotype causes an increase in the free
energy. As seen in figure 2 of the main text, the disease potential
has an opposite sign in healthy and diseased patients but about to
the same extent in either direction as shown schematically in this
figure. The figure shows only one horizontal axis but there can be
other axes in orthogonal directions representing additional,
secondary, phenotypes, for example representing the distinction
between the de novo and the recurrent states.
(DOCX)
Table S1 miRNAs greatest free energy contribution to
the in the balanced state.
(DOCX)
Table S2 miRNAs greatest negative free energy contri-
bution to the GBM-specific phenotypic state.
(DOCX)
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Table S3 miRNAs greatest positive free energy contri-
bution to the GBM-specific phenotypic state.
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Table S4 Overlap of signatures between UCLA GBM
Cohort and TCGA GBM Cohort.
(DOCX)
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